RTP Mobile Logo
Identifying, Managing and Mitigating Therapy-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (Faculty Presentation)
Released November 2021

Featuring a slide presentation and related discussion from Dr Daniel Lenihan. Published November 4, 2021. (Faculty Presentation)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows, cardiologists and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.


    • Appreciate the frequency and severity of various therapy-related adverse events (AEs) commonly encountered by patients undergoing treatment with BTK and Bcl-2 inhibitors for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and enact effective monitoring processes and procedures for appropriate individuals.
    • Recall strategies commonly employed to identify, manage and mitigate AEs associated with these agents, and, when necessary, use this information to appropriately intervene in patients for whom toxicities are suspected or diagnosed.
    • Compare and contrast the side-effect and toxicity profiles of the various FDA-approved BTK and Bcl-2 inhibitors, and recall the patient- and disease-specific factors affecting the decision to commence treatment with one versus the others.
    • Appraise the role of multidisciplinary specialists, such as cardio-oncologists and rheumatologists, in the management of treatment-related AEs, and effectively collaborate with these clinicians to offer best-practice care for patients with CLL and MCL experiencing these toxicities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AdverseEventsCLLandMCL21/Presentation/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Richard R Furman, MD
    Director, CLL Research Center
    Weill Cornell Medicine
    New York, New York

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Sanofi Genzyme; Data and Safety Monitoring Board/Committee: Incyte Corporation; Speaking Engagements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd.

    Daniel J Lenihan, MD
    President, International Cardio-Oncology Society
    Professor and Director, Cardio-Oncology Center of Excellence
    Washington University in St Louis
    St Louis, Missouri

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eidos Therapeutics, Ipsen Biopharmaceuticals Inc, Prothena; Consulting Agreements and Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc; Contracted Research: Myocardial Solutions Inc.

    Lindsey Roeker, MD
    Assistant Attending Physician
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: Aptose Biosciences, Pfizer Inc; Ownership Interest: Abbott Laboratories.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Abbvie Inc and AstraZeneca Pharmaceuticals LP.

    Release date: November 2021
    Expiration date: November 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):